tolebrutinib
sanofi
['sanofi']
we re presenting new data on our investigational btk inhibitor for #multiplesclerosis: #ectrims2022 
The home for science focused news and stories from @Sanofi, demonstrating our innovation, expertise, and industry activity. Terms: https://t.co/VH0B6o0uyQ